PARP Inhibitors Market Report- Expansive Coverage on the Profit Sources

The global PARP Inhibitors Market Size is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 15.5 Billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034.

Request For Free Sample Pages :
https://www.insightaceanalytic.com/request-sample/1169

Poly (ADP-ribose) polymerase (PARP) inhibitors target a family of 17 enzymes responsible for catalyzing the formation of ADP-ribose chains (PAR chains) and transferring them to specific target proteins. These enzymes play a critical role in DNA repair processes. DNA damage can result from various factors, including UV radiation, ionizing radiation, certain chemotherapeutic agents, and environmental chemicals. PARP inhibitors block the activity of enzymes essential for repairing single-stranded DNA breaks. By impairing this DNA repair mechanism, these inhibitors can induce cell death, particularly in cancer cells that lack alternative DNA repair pathways.

The anticipated global increase in the elderly population is expected to drive demand for PARP inhibitors. Individuals aged 65 and older are more susceptible to the onset and progression of various diseases, including chronic disorders. The population of this age group is projected to double in the coming years, further boosting the demand for PARP inhibitors worldwide. However, the market's growth may face challenges due to the development of resistance to PARP inhibitors and their limited efficacy in certain patient populations.

List of Prominent Players in the PARP Inhibitors Market:
• Johnson & Johnson Services, Inc.
• Merck KGaA
• GSK plc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Artios Pharma
• Genentech, Inc.
• Karyopharm Therapeutics Inc.
• Repare Therapeutics Inc
• ONO PHARMACEUTICAL CO., LTD
• Jiangsu Hengrui Pharma Co., Ltd.
• Bristol-Myers Squibb Co
• AstraZeneca plc
• Checkpoint Therapeutics, Inc.
• Eisai Co., Ltd.
• IMPACT Therapeutics
• JEIL PHARMA CO., LTD.
• Kyowa Kirin Co., Ltd
• SyntheX

Market Dynamics:
Drivers-
A primary factor driving the growth of the PARP inhibitors market is the rising global incidence of prostate cancer. According to the World Cancer Research Fund, prostate cancer is the second most common cancer among men and ranks fourth overall among all cancers. Additionally, the expanding use of Olaparib in advanced first-line therapy for prostate cancer is expected to further boost demand for PARP inhibitors in this segment.

Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1169

Challenges:
Sustained market growth may be constrained by intense competition among pharmaceutical companies developing PARP inhibitors. This competitive environment can result in market saturation, pricing pressures, and challenges in differentiating products. Moreover, the substantial costs associated with research, development, and clinical trials of PARP inhibitors pose significant financial risks. High development expenses may limit the entry of new players and influence pricing strategies, thereby affecting overall market dynamics.

Regional Trends:
North America is projected to hold a significant share of the PARP inhibitors market and is expected to register a strong CAGR in the coming years. A key trend driving growth in the region is the integration of genomic testing into routine oncology practice, supported by advanced healthcare infrastructure and heightened awareness. This facilitates widespread genetic screening for mutations, enabling targeted therapies with PARP inhibitors. In Europe, collaborative initiatives between academic institutions and pharmaceutical companies are increasingly shaping the market. Strategic partnerships and joint research efforts aim to accelerate clinical trials, expand treatment indications, and optimize the application of PARP inhibitors across multiple cancer types.

Recent Developments:
• In 2023, an acquisition of CinCor Pharma, Inc. was announced by AstraZeneca in order to enhance its cardiorenal pipeline. CinCor's candidate medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI), is being integrated into this strategic approach to address resistant to treatment hypertension by reducing blood pressure.
• In 2022, AstraZeneca and G42 Healthcare have formed a strategic partnership to produce pharmaceutical products in Abu Dhabi. The objective of this partnership is to improve the local manufacturing capabilities and facilitate the production of essential pharmaceuticals, thereby increasing the accessibility of healthcare in the region.
• In 2022, Helio Genomics, in collaboration with Fulgent Genetics, has obtained a new Category I CPT code from the AMA for HelioLiver, thereby facilitating the widespread implementation of advanced surveillance tests for liver cancer in the United States. This accomplishment broadens the company's market presence and product line.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customization/1169

Segmentation of PARP Inhibitors Market-
By Product-
• Niraparib (Zejula)
• Olaparib (Lynparza)
• Rucaparib (Rubraca)
• Talazoparib (Talzenna)
• Veliparib
• Other Pipeline Drugs
By Indication-
• Ovarian Cancer
• Breast cancer
• Prostate and Pancreatic Cancer
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Get More Information :
https://www.insightaceanalytic.com/report/global-parp-inhibitors-market-/1169

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Official Site Visit: www.insightaceanalytic.com
Tel.: +1 607 400-7072
Email: info@insightaceanalytic.com
Follow US On :
LinkedIn @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Twitter @ https://x.com/MInsightace
YouTube @ https://www.youtube.com/@InsightAceAnalytic
Instagram @https://www.instagram.com/insight_ace_analytic/

This release was published on openPR.